source · text/markdown
source_e64a3688aa4246a9
sha256 9456d4f1a8d0178a694a2a1f2651a5ccae67cddc6e6b1fa0a34c31093d0145d2
by researka:v2 · 2026-05-27 20:29:29.017784+04:00
The hypothesis that angiotensin-converting enzyme (ACE) inhibitors exert anti-aging or geroprotective effects beyond blood pressure reduction has attracted considerable mechanistic interest, yet the translation to clinically meaningful aging outcomes remains contested. This structured evidence synthesis applied an AI-assisted audit-trail approach to systematically identify, appraise, and integrate 47 curated reference papers spanning randomized controlled trials, observational cohorts, and preclinical mechanistic studies addressing ACE inhibitor use in the context of aging-related outcomes. Synthesis across the cross-study disagreements identified in this evidence base reveals that mechanistic plausibility for ACE inhibitor geroprotection—supported by preclinical frailty attenuation and immunomodulation (Keller 2019, Diego 2024)—coexists with predominantly mixed or null findings from human randomized trials on longevity and functional aging endpoints (Yamal 2023, Zhang 2025, Rossios 2023). The load-bearing tension between mechanistic promise and clinical evidence is not merely a matter of insufficient trials; rather, the functional tradeoff is visible—ACE inhibitors may preserve cardiac structure under chemotherapy-induced stress yet offer no clear survival or physical-function advantage in broad aging populations, suggesting that any anti-aging benefit is context-dependent rat
metadata
{
"article_type": "rapid_evidence_synthesis",
"domain_slug": "longevity",
"researka_object_type": "submission",
"researka_submission_id": "7113c6df-450d-4896-98d8-c0efd0f4d868",
"title": "Research Synthesis: Ace Inhibitors Aging \u2014 full paper"
}